相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lapatinib and Gemcitabine for Metastatic Pancreatic Cancer A Phase II Study
Howard Safran et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2011)
Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer
Hyun-Jin Nam et al.
CANCER LETTERS (2011)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer
Masahiro Komoto et al.
CANCER SCIENCE (2010)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer
Xiong Cai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities
Helmout Modjtahedi et al.
ANTI-CANCER DRUGS (2009)
HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy
Samanthi A. Perera et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents:: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
Helena Linardou et al.
LANCET ONCOLOGY (2008)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
D. Li et al.
ONCOGENE (2008)
ErbB receptors: from oncogenes to targeted cancer therapies
Hongtao Zhang et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors
Elizabeth Buck et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Epidermal growth factor receptor targeting in cancer
John Mendelsohn et al.
SEMINARS IN ONCOLOGY (2006)
Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib
Matthew P. Cunningham et al.
CANCER RESEARCH (2006)
Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas:: lack of mutations in the BRAF and EGFR genes
Heike Immervoll et al.
VIRCHOWS ARCHIV (2006)
Epidermal growth factor receptor (EGFR) signaling in cancer
N Normanno et al.
GENE (2006)
An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor
S Kobayashi et al.
CANCER RESEARCH (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme
CA Learn et al.
CLINICAL CANCER RESEARCH (2004)
Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): Combining anti-EGFR antibody with tyrosine kinase inhibitor
SM Huang et al.
CANCER RESEARCH (2004)
Pharmacological background of EGFR targeting
L Castillo et al.
ANNALS OF ONCOLOGY (2004)
Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225):: Superiority over single-agent receptor targeting
P Matar et al.
CLINICAL CANCER RESEARCH (2004)
Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRVIII) by anti-EGFR MAb ICR62: A two-pronged attack for tumour therapy
H Modjtahedi et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Treatment of pancreatic cancer xenografts with erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation
DJ Buchsbaum et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers
L Laghi et al.
ONCOGENE (2002)
The ErbB signaling network: receptor heterodimerization in development and cancer
MA Olayioye et al.
EMBO JOURNAL (2000)
分享论文
